Autopsy report · NCT04762511

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“To enable development of an enhanced version of the vaccine”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 3 months before it stopped.
17 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: GlaxoSmithKline
Sponsor type: Industry
Conditions: Herpes Simplex
Interventions: Lower dose formulation of HSV vaccine (GSK4108771A); Low dose formulation of HSV vaccine (GSK4108771A); Medium dose formulation of HSV vaccine (GSK4108771A); High dose formulation of HSV vaccine (GSK4108771A); Placebo (saline)
Participants: 17
Sites: 2
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.